Roche Analyst Event at ASCO 2013

Analyst briefing on data presented at ASCO: Sunday, 2 June 2013 6:30 PM CDT



  • Obinutuzumab (GA101) + chlorambucil (Clb) or rituximab (R) + Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and pre-existing medical conditions (comorbidities): final stage I results of the CLL11 (BO21004) phase 3 trial
    Valentin Goede, MD, German CLL Study Group; Dept. I of Internal Medicine, University Hospital Cologne and Dept. of Geriatric Medicine and Research St. Marien-Hospital Cologne
  • Oncology pipeline update
    Hal Barron, MD, Chief Medical Officer and Head, Global Product Development
  • Oncology business and strategy update
    Daniel O’Day, COO Roche Pharmaceuticals Division